There is a warning in the prescribing information for IL-17A antibodies for patients with IBD, and active Crohn’s disease is a contraindication to the use of the IL-17 antibody brodalumab (Whitlock et al., 2018). The gene discussed is IL17A; the disease is inflammatory bowel disease.